New Roche Dual Target HIV-1 Test Approved for Use in European Union Dec 15, 2008
Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. (PR Newswire)
Do You Have the Guts to Buy? Dec 15, 2008
Genentech (NYSE: DNA) had more than doubled since October. Wall Street darlings from Biogen Idec (Nasdaq: BIIB) to Genzyme (Nasdaq: GENZ) were blowing up. (MSNBC -- Business)
PRO'S PICKS: Stocks to watch in 2009 Dec 15, 2008
Investment Roundtable: Stocks to watch in '09 - USATODAY.com. Real solutions for your real estate needs. (USA Today -- Money)
California's rich keep on giving Dec 14, 2008
Genentech Access To Care Foundation: 194. 1. (Yahoo News -- Philanthropy and Volunteerism)
Biotech Team-Up Dec 13, 2008
Its partners in the development of those compounds include Genentech Inc. and Wyeth. Exelixis will end the year with $280 million in cash, Scangos said. (San Francisco Chronicle -- Business)
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial Dec 13, 2008
In the US, Herceptin is a registered trademark of Genentech, Inc. Internationally, Herceptin is a registered trademark of Roche. Taxol is a registered trademark of Bristol-Myers Squibb Company. (PR Newswire)
Small breast tumors may need more treatment Dec 13, 2008
She has no financial ties to Herceptin's maker, California-based Genentech Inc., but some of her co-authors do ... "The implication would be that they might benefit from treatment," but that wasn't tested in the Texas study, said Brown, who has no ties to Genentech. (MSNBC -- Health)
Study of Tumor Recurrence May Change Drug Guidelines Dec 13, 2008
Today, a targeted therapy called Herceptin, made by the biotech company Genentech, has greatly improved the odds for women with HER2-positive cancer. Recent studies show the drug reduces the recurrence of these cancers by about half. (Atlanta Journal-Constitution -- Health)
New data from largest-ever clinical trials in CLL show Rituxan (Rituximab) enables leukemia patients to live longer without their disease progressing Dec 12, 2008
" Professor Michael Hallek, University Hospital Cologne, Germany, who led the German CLL Study Group (GCLLSG) in conducting the CLL8 trial said, "With new therapies emerging, the management of CLL is set to change markedly, with physicians having more options and greater treatment expectations for their patients. These data, which come from the largest randomized clinical trials ever reported in CLL, suggest that Rituxan (MabThera) used in combination with chemotherapy has the potential to... (Canada Newswire)
The Year's Best Funds? Dec 11, 2008
Its roster does include stocks with positive returns for the year, such as Genentech (NYSE: DNA) and Cryolife, but beware its astronomical 7. 2% annual fee. (MSNBC -- Business)
For biotech, a tax break spells hope Dec 10, 2008
The big profitable biotech companies like Amgen and Genentech remain financially sound ... The chief executive of Genentech has estimated the industry as a whole has lost about $100 billion since the field's inception in 1970s. (International Herald Tribune)
'This is your family Dec 9, 2008
Her client list includes Microsoft, Pfizer, Genentech and Chrysler. "I got into this when I realized that so many people just complained about relationships. They didn't realize that they can assert themselves in a polite and powerful manner," she says. (NJ.com -- Times)
tp_bulkViewer.add("itemnumcomments","id=z43dd68e3df0c80b38825751600644cb1"); Dec 6, 2008
BIOTECH: Roche bid for Genentech hits credit turbulence : North County Times - Californian ... BIOTECH: Roche bid for Genentech hits credit turbulence ... OCEANSIDE ---- A 45 billion takeover bid for Genentech announced in July still has not closed as the end of the year approaches, increasing uncertainty about whether the deal will take place. (North County Times)
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives Dec 4, 2008
"We are successfully translating the broad applicability of our technology into opportunities for both novel human therapeutics and non-therapeutic industrial applications. Our unique hybrid business model maximizes the value of our ZFP technology platform and has enabled us to make significant progress in moving our lead ZFP Therapeutic into multiple Phase 2 clinical trials and advancing our preclinical pipeline, while maintaining a strong balance sheet. We have established important commercial... (PR Newswire)
Business.view: The urge to merge Dec 3, 2008
7 billion acquisition of Genentech, but this claim is being met with growing scepticism. That is now. (The Economist)
Remedy Announces New Account Supervisor Dec 2, 2008
There she served as an account lead on clients such as Genentech and MedImmune. LaClair has extensive experience in healthcare, including accounts such as Abbott Laboratories, Pfizer, GSK, Eli Lilly and Cyberonics. (PR Newswire)
Asian Journal of Andrology Dec 2, 2008
2007 impact factor 1. 609* 3/5 (Andrology); 33/55 (Urology ology). (Nature News Service)
Chances dim for Roche deal for Genentech Dec 2, 2008
The prospects that Roche, the Swiss drug maker, can raise a $45 billion syndicated loan to finance the buyout of the rest of Genentech, the U.S. biotechnology group, are becoming increasingly remote ... 7 billion bid to acquire the 44 percent of Genentech that it does not already own ... This, along with cash on Genentech's balance sheet and Roche's own cash flow, could reduce the amount of debt to raise, bankers said. (International Herald Tribune -- Business)
Prospects of $45 Bln Loan for Roche Receding Dec 1, 2008
LONDON (Reuters) - The prospects of Swiss drugmaker Roche raising a $45 billion syndicated loan to finance the buyout of the rest of U.S. biotech group Genentech are becoming increasingly remote ... 7 billion bid to acquire the 44 percent of Genentech it doesn't already own. (ABC News -- Wire)
IR Global Rankings 2009: Final Registration Deadline Is Today - November 28, 2008 Nov 29, 2008
TW); Cyrela (Bovespa: CYRE3); Daimler (NYSE: ); Danske Bank (XETRA: DSN.DE); Datasul (Bovespa: DSUL3); Deutsche Post World Net (XETRA: DPW.DE); Deutsche Telekom (NYSE: ); E*Trade Financial (NASDAQ: ); Enersis (NYSE: ); Erste Bank (EUX: EBO.EX); Estacio Participacoes (Bovespa: ESTC3); Euro Disney (Paris: EUROD.PA); EVN (OTC: EVNVY.PK); Exxaro Resources (OTC: EXXAY.PK); FedEx (NYSE: ); Gafisa (NYSE: ); Genentech (NYSE: ); General Electric (NYSE: ); Global Payments (NYSE: ); Global Sources (NASDAQ:... (PR Newswire)
Giants impact community in big ways Nov 27, 2008
Lincecum's total went a long way toward helping Giants pitchers amass 624 strikeouts at ATmpting the Genentech Foundation to donate $200 per K to the Wellness Community, a Bay Area-based cancer support organization, as part of the season-long Strike Out Cancer program. The $124,800 raised this year hiked the total contribution since the program's inception in 2004 to more than a half-million dollars. (MLB.com -- San Francisco Giants)
Mining deal's collapse bodes ill for investment banks Nov 27, 2008
Mining deal's collapse bodes ill for investment banks - International Herald Tribune. The collapse of BHP Billiton's $66 billion takeover of Rio Tinto robs bankers of one of the few chunky deals left as their business crumbles in the credit crisis. (International Herald Tribune -- Business)
Scientists shed light on causes of epilepsy Nov 25, 2008
The treatment worked in a similar way to Elan Corp Plc's multiple sclerosis drug Tysabri and Genentech Inc's Raptiva for psoriasis, she added. This means these kinds of drugs might also one day be used to treat epilepsy and the findings could also lead to new anti-inflammatory treatments for epilepsy, she said. (MSNBC -- Health)
Study Data on Avastin Bolster Genentech Stand Nov 25, 2008
Genentech Inc. said a major study found Avastin delayed progression of breast cancer when combined with commonly used chemotherapies, strengthening the case for the blockbuster drug's use as first-line treatment in patients with advanced disease ... biotechnology company's argument for a higher offer from Roche Holding AG for the 44% of Genentech it doesn't already own. (Wall Street Journal)
Genentech: Progress In Trial Of Avastin For Breast ... Nov 24, 2008
Genentech: Progress In Trial Of Avastin For Breast Cancer - FOXBusiness ... Genentech: Progress In Trial Of Avastin For Breast Cancer ... TEL AVIV -- Genentech Inc., the South San Francisco biotech major, said that in a Phase III study, Avastin -- combined with taxane, anthracycline-based or capecitabine chemotherapies for first-line treatment of metastatic HER2-negative breast cancer -- "met its primary endpoint of increasing the time patients lived without their disease advancing, compared... (Fox News)
Don't Make a Million-Dollar Mistake Nov 23, 2008
Should you opt for growth stocks such as Genentech (NYSE: DNA), Medtronic (NYSE: MDT), and Qualcomm (Nasdaq: QCOM), each of which sports juicy earnings-growth estimates and -- surprise, surprise -- S&P-beating price-to-earnings (P/E) ratios as well. Teva Pharmaceutical (Nasdaq: TEVA), Baxter International (NYSE: BAX), and PDL BioPharma (Nasdaq: PDLI) continue to fit that bill, too. (MSNBC -- Business)
Avastin Raises Risk of Blood Clots in Veins Nov 21, 2008
An analysis of 15 clinical trials involving nearly 8,000 people found Avastin, marketed by Roche and Genentech, raises the risk of a blood clot in the veins from about 10 percent of patients to about 13 percent ... "It's not a new safety signal for Avastin. The risk is referenced in the adverse reaction section of the label," said Charlotte Arnold, a spokeswoman for Genentech. (MEDLINEplus)
FOXBusiness: Dow Plummets Below 8,000 Nov 20, 2008
I dont see anything great on the horizon, but I dont see things getting much worse," NYSE trader Jason Weisberg of Seaport Securities told FOX Business. Led by a steep decline from Yahoo! (YHOO), the Nasdaq Composite ended at its lowest level since April 2003. The index has now lost more than half of its value since its multi-year high of 2859 hit in October 2007. There was no shortage of bearish headlines pulling the markets down: a prediction by the Fed for economic contraction through... (Fox News)
Smiling Through the Sell-Off Nov 20, 2008
Meanwhile, while the market has been in free fall over the last 12 months, Wal-Mart (NYSE: WMT), Genentech (NYSE: DNA), and General Mills (NYSE: GIS) have actually managed to notch gains. Bandages for your portfolioThen there's the fate of fund investorsversus folks whose portfoliosinclude just individual picks. (MSNBC -- Business)
Cash-Rich Drugmakers Eye Mergers or Acquisitions Nov 20, 2008
7 billion to buy the 44% of biotech bigwig Genentech (DNA) that it didn't already own. Genentech's executives turned down Roche's offer of 89 per share, saying it was too low. (Yahoo News -- Pharmaceutical Industry News)
PDL plans biotech unit spinoff by Dec. 18 Nov 20, 2008
PDL will continue as a publicly traded company, reaping millions of dollars from royalties from its antibody humanization patents from the likes of (NYSE: DNA) and This year, royalties from the sales of Genentech s Avastin, Herceptin, Xolair, Raptiva and Lucentis and other companies products, will bring in $270 million to $280 million. After the spinoff, PDL will move from Redwood City to an undisclosed location outside California, CFO Andrew Guggenhime said Nov. 6. (San Francisco Business Times, CA)
Genentech's Avastin linked to vein-clotting risk in analysis Nov 20, 2008
Genentech's Avastin linked to vein-clotting risk in analysis - San Jose Mercury News ... Genentech's Avastin linked to vein-clotting risk in analysis ... Genentech's Avastin, widely prescribed for colon cancer and some lung tumors, was linked to significantly higher rates of vein clotting in an analysis of earlier studies. (San Jose Mercury News)
Avastin Blood Clot Risk Nov 19, 2008
Genentech disputes new Avastin research data. Article:Genentech disputes new Avastin research data:/c/a/2008/11/18/BUKB146FD8 ... DTL Article:Genentech disputes new Avastin research data:/c/a/2008/11/18/BUKB146FD8. (San Francisco Chronicle -- Business)
Blindness was about to take Lorna Ball's driver's licence - until a new treatment gave her back her sight and left her behind the wheel Nov 19, 2008
Lucentis(*) was developed by Genentech and Novartis. Genentech has the commercial rights to Lucentis(*) in the United States, while Novartis has exclusive rights in the rest of the world. (Canada Newswire)
Genentech disputes new Avastin research data Nov 19, 2008
(11-18) 17:43 PST SAN FRANCISCO -- Genentech's blockbuster cancer drug Avastin is linked to a significantly increased risk of blood clots in the veins, said a team of university researchers whose conclusions were quickly challenged by the big biotechnology company ... Wu's study contradicts the conclusions from a pooled analysis of five studies by Genentech researchers, who reported in 2007 that the vein clots did not rise significantly among subjects on Avastin ... Avastin, marketed by... (San Francisco Chronicle)
Verizon fires 14, alleges false reporting of hours Nov 18, 2008
A 2d psoriasis patient has died of PML Genentech Inc. reported that a second patient who was taking the company's psoriasis treatment, Raptiva, has died after developing a rare brain infection ... -based Genentech said in a prepared statement ... Genentech reported on Oct. 14 that a 70-year-old patient who also was taking the drug for more than four years had died from PML. The two cases suggest "prolonged exposure to Raptiva and older age" may further increase the risk for patients of... (Boston Globe)
Apple Winning Over Businesses with iPhone Nov 17, 2008
A handful of companies, such as Genentech and Disney, mostly with ties to Apple, have decided to adopt the iPhone companywide as a communications tool. Such decisions are not hurting Blackberry significantly, as they often come from companies that had not previously adopted a smartphone in mass. (DailyTech)
Biotechs claw for their lifeblood - financing Nov 17, 2008
By contrast, shares in giant industry leaders, including Genentech and Amgen, rose this year. Some of those big companies are even hiring. (San Francisco Chronicle)
Volatility Alert: Economic Data leads to Declines for Stocks Nov 17, 2008
Selling continued this past week, although the lows were successfully retested. The Dow ($) fell 446. (Forbes -- Markets)
Predictive Tests And Early Treatment Delay Progression Of Blood Cell Cancer, Researchers Find Nov 16, 2008
15, 2008) Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL). (Science Daily)
Roche sticks by $43.7 billion Genentech bid: report Nov 14, 2008
7 billion Genentech bid: report - Yahoo ... 7 billion Genentech bid: report ... 7 billion offer to buy out the rest of Genentech Inc (DNA.N) it does not already own, its pharmaceuticals chief said in an interview published on Sunday. (Yahoo News -- Pharmaceutical Industry News)
Europe Retreats from M&A Deals in U.S. as Japan Emerges: Chart of the Day Nov 13, 2008
8 billion, including debt, or Swiss drugmaker Roche Holding AG's offer to buy Genentech Inc. for $41. 3 billion. (Bloomberg -- Asia)
Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Nov 9, 2008
Genentech, co-marketer of Xolair, plans to submit these data to the US Food and Drug Administration (FDA) seeking to expand the current labeled indication for Xolair ... Xolair is co-marketed in the United States by Genentech, Inc. and Novartis Pharmaceuticals Corporation. (PR Newswire)
Will Apple iPhone overtake Blackberry in the corporate segment? Nov 9, 2008
At the time, big names like Genentech Inc, Nike Inc and Walt Disney Co announced they would support the iPhone. Genentech said it would deploy 3,000 to employees. (India Times)
Tarceva maker: Study shows drug slows lung cancer Nov 8, 2008
Genentech and Roche Holdings are partners with OSI in the development and marketing of Tarceva ... In the Saturn study conducted by Roche, 889 patents were enrolled at 160 sites worldwide, according to a joint news release by OSI and Genentech ... In a statement, Hal Barron, Genentech's chief medical officer, said that the findings "represent another step forward in our hopes of providing more options to patients ...". (Newsday)
Brain cells in mice coaxed to regenerate Nov 7, 2008
In your arms and legs, if these fibers are severed, they can regrow back to the muscle, said Marc Tessier-Lavigne, executive vice president of research drug discovery at biotechnology firm Genentech Inc.. Nerve fibers in the brain and spinal cord do not regenerate. (MSNBC -- Health)
Optic nerves regrowth raises hope for blind Nov 7, 2008
In the same journal a second team from the US biotech company Genentech reports similar experiments that prompted the regrowth of nerve cells in petri dishes. Both studies looked at nerve fibres called axons, which carry electrical signals around the body. (guardian.co.uk)
Newsweek: How we should fix biomedical research Nov 4, 2008
It's made billions for Genentech. Herceptin increased the cure rate for high risk Her-2 positive breast cancers by 50%, another multi-billion dollar blockbuster. (MSNBC -- Health)
Genentech seeks Avastin OK for brain use Nov 4, 2008
Genentech seeks Avastin OK for brain cancer - Sacramento Business Journal ... Genentech seeks Avastin OK for brain cancer ... If the Food and Drug Administration accepts Genentech s application to use Avastin against previously treated glioblastoma, accelerated approval would allow provisional approval based on preliminary evidence suggesting there is a benefit. (Sacramento Business Journal, CA)
California's rich keep on giving Nov 4, 2008
Genentech Access To Care Foundation: 194. 1. (Yahoo News -- Philanthropy and Volunteerism)
Election to benefit some industries, harm others Nov 4, 2008
Unlike traditional chemical drugs, biotech companies such as Amgen Inc. and Genentech Inc. face no generic competition in the U.S. because the Food and Drug Administration lacks authority to approve copies of biotech medicines. That is because biotech drugs, which are made from living cells or bacteria, are more complicated to manufacture than chemical drugs. (San Diego Union-Tribune -- Business)
U.S. biotech IPOs dying on the vine Nov 1, 2008
Swiss drugmaker Roche Holding is trying to buy the shares in Genentech it does not already own for $43. 7 billion, while Eli Lilly recently acquired ImClone Systems for $6. (USA Today -- Tech)
Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform Oct 31, 2008
Roche has Rements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R007. Worldwide, the Group employs about 80,000 people. (PR Newswire)
Drugmaker Roche plans expansion at Ventana Oct 30, 2008
Ventana developed an automated test that can detect the gene's presence and quantity, which indicates whether a patient may benefit from Herceptin, which is sold in the United States by Genentech Inc. Roche owns a majority of California-based Genentech's stock and has made a bid to buy the rest. That type of personal health care is potentially a big industry and of great benefit to patients, Schwan said. (AZCentral -- Business)
State Fund opens $77M green office in Vacaville Oct 30, 2008
The site is located south of Genentech s Vacaville facility, and east of Interstate 505. State Fund said materials once destined for landfills made up more than 20 percent of the building materials used in its construction, including concrete and cork and rubber flooring. (East Bay Business Times, CA)
Broader Financial Turmoil Threatens Biotech's Innovation and Cash Oct 29, 2008
The big biotechnology companies, including Genentech and Amgen, have products on the market and are highly profitable. The biggest companies are in such strong financial shape, in fact, that their shares are roughly flat for the year, far better than stocks as a whole. (Atlanta Journal-Constitution -- Business)
Venture capital firm closes on $250m high-tech fund Oct 28, 2008
Genentech, of South San Francisco, Calif. is seeking to expand its current US approval for Rituxan. (Boston Globe)
The Millionaire in the Next Cubicle Oct 27, 2008
It should also provide a fund whose managers look toward growth-oriented fare such as Genentech (NYSE: DNA) and Qualcomm (Nasdaq: QCOM) -- stocks with robust earnings-growth estimates over the next five years. Taiwan Semiconductor (NYSE: TSM) and Research in Motion (Nasdaq: RIMM) are similarly racy contenders for such funds. (MSNBC -- Business)
Samsung drops bid for SanDisk as mergers decline globally Oct 24, 2008
A $44 billion offer by the Swiss drug maker Roche for Genentech of the United States remains on the table after Roche on Tuesday confirmed its commitment to buying the 46 percent of Genentech it did not already own. But Genentech, a biotechnology company, has rebuffed the offer as inadequate. (International Herald Tribune -- Technology)
5-Star Stocks Poised to Pop: Genzyme Oct 24, 2008
Genentech (NYSE: DNA). Amgen (Nasdaq: AMGN). (MSNBC -- Business)
New Prostates Grown from Single Stem Cell Oct 24, 2008
But study co-author Leisa Johnson, a senior scientist with Genentech in San Francisco, said that point has not yet been proven. In rodents, the normal prostate undergoes up-and-down cycles of androgen (a male hormone), indicating to researchers the presence of prostate stem cells. (MEDLINEplus)
Merck's Free Radical Oct 24, 2008
Noticeably absent are drugs such as Genentech (nyse: - - )'s $2 billion (annual sales) Avastin, which stanches tumor blood supply. These are too complicated to understand. (Forbes -- Business)
Prostate Gland, a Repository of Adult Stem Cells, Genentech ... Oct 24, 2008
Prostate Gland, a Repository of Adult Stem Cells, Genentech Researchers Found ... Prostate Gland, a Repository of Adult Stem Cells, Genentech Researchers Found ... Researchers at Genentech, in San Francisco, found that the prostate contains adult stem cells that are capable of building a new prostate gland. (eFluxMedia)
Growing Prostates from Adult Stem Cells -- But Who Would Want One? Oct 23, 2008
By homing in on the researchers can now examine how this cell population helps regulate growth in the prostate, says Leisa Johnson, a molecular biologist at Genentech, Inc., in South San Francisco, Calif. and co-author of the study appearing in Nature. (Scientific American)
Hope for new cancer drugs as scientists grow prostate gland from a ... Oct 23, 2008
The study by researchers at Californian firm Genentech suggests that the stem cells may fuel the pre-cancerous growth of the prostate and ease the disease's passage around the body. Learning more about how they do this could lead to new ways of combating the disease. (Daily Mail)
